Organon Outlines Importance Of Speed For US Humira Opportunity
Former Merck Company Also Divulges Interchangeability Expectations
At its debut year-end financial earnings call, Organon spoke in further detail about the impending launch of Humira biosimilars, as well as its desire to continue growing its portfolio.
You may also be interested in...
Organon CEO Kevin Ali has acknowledged that the long-term future for the biosimilars business is unclear, despite the firm’s biosimilars segment currently acting as a solid growth driver for the company.
Organon commercial director and lead for the South Asia Region, Anjan Sen, lays out how the Merck spin-out expects to scale up activities in markets like India. A mix of new products, targeted repurposing efforts and access-driven pricing are part of the strategy that could potentially see the company double its presence in the region.
While awaiting news from the FDA for its biosimilar application referencing the higher-concentration formulation of Humira, Alvotech has announced that the FDA has accepted its BLA supporting interchangeability for the AVT02 candidate.